Bonum Certa Men Certa

Orrin Hatch, Sponsored the Most by the Pharmaceutical Industry, Tries to Make Its Patents Immune From Scrutiny (PTAB)

American (US) pharmaceutical patents on Canadian soil are meanwhile at risk as a result of Trump's trade war that invites retaliation

Orrin Hatch's funding
Source: OpenSecrets



Summary: Orrin Hatch is the latest example of laws being up for sale, i.e. companies can 'buy' politicians to act as their 'couriers' and pass laws for them, including laws pertaining to patents

THE SCOTUS issued some important rulings such as Alice and Mayo, which meant that patents granted by the USPTO may, in retrospect, be invalid. The Saint Regis Mohawk Tribe is attempting to shield Allergan from the Patent Trial and Appeal Board (PTAB), the only tribunal that can render Allergan's patents invalid unless Allergan sues. All sorts of pharmaceutical patents are under a similar threat from PTAB and Mr. Kyle Bass made headlines some years ago when he used PTAB as a 'weapon'. His 'threat' was ending a monopoly.

The subject of immunity from PTAB is now at the Federal Circuit and we need to question the motivation of politicians who take Allergan's side, even based on their sources of funding alone.

"Watchtroll likes to heckle politicians who receive money from technology firms, but what about pharmaceutical firms?"To be clear, in the area of technology pretty much all the companies -- both large and small -- support PTAB, except a few like IBM, which nowadays relies on patent shakedowns rather than sales (we have been saying this for years [1, 2, 3, 4, 5]). Watchtroll likes to heckle politicians who receive money from technology firms, but what about pharmaceutical firms? Or law firms (third in Orrin Hatch's list)? We'll come to that in a moment. In case it's not obvious, in the pharmaceutical sector the notion of patent trolls is rare and practically ineffective because the number of producing firms is relatively small. It just doesn't scale. So PTAB is of virtually no use for large pharmaceutical firms; it mostly puts them under the 'threat' from generics (we use scare quotes because this the real threat is a threat to people's lives due to the price of certain medicine -- monopolised medicine).

The USPTO's SAS decision "isn't good for the efficiency of the PTAB inter-partes review (IPR)," Florian Müller wrote a short time ago (as noted in yesterday's post of ours), unlike Oil States. Here are some passages:

Samsung challenged multiple claims of two of Huawei's patents-in-suit. The USPTO decided to institute reexamination with respect to some of them, but it had to issue a supplemental order in the wake of SAS and look--nolens volens--at all challenged claims, though it encouraged Samsung to drop its challenge to the ones with respect to which the USPTO was originally unconvinced.

Huawei had actually focused, for the purposes of infringement litigation, on the claims the USPTO viewed more favorably, but the SAS decision changed everything.

As I wrote in my commentary on SAS, this isn't good for the efficiency of the PTAB inter-partes review (IPR) process, but the conservative Supreme Court majority was right that the way the law was worded didn't leave room for any other decision, short of legislating from the bench, which most justices declined to engage in.


There have long been attempts to slow down if not shut down PTAB. These attempts came mostly from pharmaceutical giants and the patent microcosm. Days ago we named involvement by Hatch. This anti-PTAB move is now being covered by Dennis Crouch and Watchtroll, who spent his Sunday badmouthing the cause of generics. To quote Crouch's take (something we already covered twice in recent days, saying we'd check Hatch's contributions to know if indeed he's in the pockets of big pharmaceutical companies):

The basics of the amendment is that the results of an IPR/PRG proceeding cannot serve as its Paragraph IV certification that the patent is invalid. A parallel provision is designed for biologics under the BCPIA.


Suddenly everyone starts talking about this; it's seen as the latest anti-PTAB angle. See Bryan Helwig's "Life Sciences Court Report" (published hours ago) and this Twitter exchange involving Senior Lecturer Luke McDonagh (who comments a lot on UPC), patent attorney Alexander Esslinger (Team UPC), and Jonathan Kimmelman (Bioethicist/Meta-scientist). "Canada is discussing to make pharmaceutical patents unenforceable in Canada aiming at US pharmaceutical industry as retaliatory action against Donald Trump‘s tariffs IP [sic] trade war," Esslinger wrote in relation to this article from CBC (Canada). To quote:

And so Attaran is suggesting that Canada take aim at U.S. drug patents.

The U.S. holds more pharmaceutical patents and other intellectual property licences than any other country. But that strength could become a vulnerability if Canada took action to suspend American patents on Canadian soil. Canadian companies would then be able to produce those drugs.

"You hit us on tariffs, we hit you on patents," he said.


Hours ago Keith Speights published "Big Pharma Stock Investors Beware: Another $250 Billion Patent Cliff Is Coming" -- an article in which he says:

How scary is the impending patent cliff? It's not as bad as you might think.

The worst brunt won't be felt until 2023. Total sales at risk due to patent expiration will actually be much lower than in recent years in 2020, 2021, and even 2024.

Also, just because sales are at risk doesn't mean that those sales will completely be lost. EvaluatePharma projects that roughly $139 billion in sales will be lost between 2018 and 2024 for drugs that go off-patent. That's a big number, but it's also much lower than the $250-plus billion in sales that are at risk during the period.

Humira, for example, is still expected to be the world's No. 1 drug in 2024, with sales of more than $15.2 billion. EvaluatePharma thinks that Revlimid will slip a spot from No. 2 to No. 3, but will still grow robustly and generate revenue of close to $8.2 billion annually seven years from now.

Johnson & Johnson has demonstrated the ability to hold on to most of the revenue for Remicade despite losing patent exclusivity. However, J&J's tactics have been controversial and spurred Pfizer to sue for alleged violation of antitrust laws.

EvaluatePharma's report noted that many analysts aren't too concerned about Novo Nordisk's patent cliff. The firm stated that sales expectations for Novo's drugs that have or will lose patent protection continue to remain relatively high, probably because of "the historical sales erosion seen for injected diabetes therapy."


The bottom line is, the value of many companies associated with medicine depends greatly on patents. We do not generally oppose such patents, but we certainly oppose making such patents immune from PTAB. This effort from Hatch is currently being exploited by the anti-PTAB lobby and Hatch seems to be motivated by bribes rather than concerns for public health. Millions of dollars for Hatch to help guard multi-billion monopolies certainly make "business sense". ⬆

Recent Techrights' Posts

Soap Opera of NVIDIA Marketing in Mainstream Media (Overhyped GPUs and Mindless Buzzwords)
NVIDIA's shares lost about $100 in "value" (or 40% "market cap" decline) in 6-7 weeks
The Boss of Linus Torvalds Has Bad Taste, Takes More Money Connected to Traffickers of Underage Girls for Sexual Exploitation Under the Guise of "Tackling Fraud"
Nothing will ever teach Jim Zemlin that Jeffrey Epstein is bad [...] Even the wife of Mr. Epsteingate was wise enough to keep a distance from it. But not Mr. Zemlin, who profits from rehabilitating abusers.
 
Calling Frauds "Frauds" is Not Illegal
We are still getting the same vibe; Americans do not understand free speech, even if their country has a First Amendment
Everything is "AI" Now
"More Open Than Open [...] I am constantly amazed at the flexibility of this single word.”
Microsoft Web Sites Paint Mass Layoffs as Opportunities for Those Impacted, Mass Layoffs Alleged to Follow in January (to 'Kill Off' Survivors)
Keeping Up Appearances
Microsoft Outages Accelerate Migrations to Free Software
More than one major outage lately
Richard Stallman's Talks Next Month (Tech de Ciudad de México)
Right now is a very good time to promote Software Freedom because of recent world events
WSJ Leadership Institute as Marketing Spam for Slop and GAFAM/IBM PR
What the heck is "WSJ Leadership Institute"?
Links 19/11/2026: "So Many Crucial Services Are Going Down" and "Government Tech Debt is a National Security Risk" (Outages Blamed on Slop Frenzy)
Links for the day
Gemini Links 19/11/2026: Friends, Slop Harms Learning, and IBM Plex Lagrange Fontpacks
Links for the day
Links 19/11/2026: "Ignorance Has Taken Over" and "Apocalypse Now, Again"
Links for the day
Richard Stallman Still Insists "They" is Plural, Suggests "Perse" Instead
this week
New Video Explains Why Software Patents Are Evil ("Why Software Patents Spark So Much Frustration")
Maybe some patent examiners (who don't mind a Facebook URL) can take a look
Intercontinental Brigading - Part XXXXXVI - Never Showing Up for Their Own Hearings, Just Paying Hired Guns in London to Act as Fall Guys and Proxies With No Comprehension of the Technical Issues (and Sometimes by Bullying Our Lawyers)
Without any qualifications in the subject at hand
Compatible With Software of 30 Years Ago
Old is not bad, sometimes old is better
NVIDIA Corporation Does Not Look Healthy
The bubble will be hard to re-inflate
Gemini Links 19/11/2026: Thinking About Thinking and Discord
Links for the day
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Wednesday, November 18, 2026
IRC logs for Wednesday, November 18, 2026
Lots of IBM Layoffs in Slovakia This Year
Slovakia and Europe at large
There May be Little or No Future for IBM Consulting
IBM is believed to be run by parasites
At Least Three RMS Talks Next Month in Mexico (Richard Stallman Has 8+ Talks in a Month)
And also - possibly with slop - in social control media
Mass Layoffs at Salesforce Foretold by Techrights
Salesforce is dead meat and it's not alone
Gemini Links 18/11/2026: Creativity, MFA Hype, and Presto Music
Links for the day
Links 18/11/2026: More GAFAM/Apple 'Clown Computing' Outages and Deutsche Bank Leak, Banks' Downtimes
Links for the day
Today The Register MS Showed Loyalty to the Pyramid Scheme With Homage of Paid Spam About "AI"
The Register MS is disavowed by its founder, who died a few years ago (The Register MS didn't even mention this)
Staff Union of the European Patent Office (SUEPO) Plans General Assembly Next Week, Vote Planned to Approve 7+ More Months of Strikes
The "Agenda" is the same as what we showed yesterday, but the pattern of the actions varies somewhat
IBM's Red Hat a Microsoft Reseller (Second Day in a Row)
If you want a replacement for Microsoft, look somewhere other than Red Hat
After the Bubble Pops the "AI Experts" (Formerly "Data Scientists" or Whatever) Will Rebrand Themselves Again
Remember blockchains and metaverse?
Links 18/11/2026: "Fossil Fuel Companies Are Undermining Democracy" and "Lawyer Up, Elon"
Links for the day
Intercontinental Brigading - Part XXXXXV - Acts of Hypocrisy (Doing What You Accuse Others of Doing)
connected to my criticism of "Restricted Boot"
Mainstream and Establishment Media Trying to Connect "Open Source" to White-Collar Crimes and Scandals at Fraudulent NVIDIA
An associate us said that "MIT lies to smear OSS"
Lawfare Will Continue in 2027
We're dealing with defiant Microsofters who wrongly assume that accurate reporting that causes them distress somehow makes them entitled to money
On the Concept of Moral Obligations to Make the World a Better Place for Everybody
The world generally becomes better when more people challenge the status quo rather than bow down to masters
Nadella Talks About 60,000 Microsoft Workers Having to Decide Whether to Leave (in the Next 2-3 Weeks), They've Been Put on Notice
Some parts of Microsoft are poised for severe cuts
IBM Moved From Selling Technology to Selling Its Buildings
IBM is trying very hard to silence/crush critics
Staff Union of the European Patent Office (SUEPO) Looking to Extend Industrial Actions and Strikes to Almost 1.5 Years
It says a lot about the media that for 1.5 years staff is on strike in the second-largest organisation in Europe and the media pretends it's not happening
Richard Stallman's Talk in Quito This Week (At Least 5 Talks After That)
He's having a busy end of year
Gemini Links 18/11/2026: "Love For Old Devices" and New Software/Slop-ware Releases
Links for the day
Over at Tux Machines...
GNU/Linux news for the past day
IRC Proceedings: Tuesday, November 17, 2026
IRC logs for Tuesday, November 17, 2026